South San Francisco-based Senti Biosciences Holdings (Nasdaq: SNTI) is divesting its gene-circuit-enabled pipeline — including its most advanced clinical asset — to a newly formed private company, restructuring itself around an earlier-stage technology platform it believes addresses a fundamental limitation of current genetic medicines.
The strategic transaction transfers the company's Gene-Circuit-enabled pipeline, including SENTI-202 (an allogeneic NK cell therapy for relapsed/refractory acute myeloid leukemia), to a newly formed private entity — referred to as NewCo — controlled by affiliates of Celadon, Senti's largest investor. In exchange, Senti's stockholders will receive a contingent value right structured around three milestone payments totaling up to USD 60 million over seven years: USD 10 million upon BLA filing and acceptance, USD 20 million upon FDA approval, and USD 30 million upon reaching USD 200 million in cumulative net sales of SENTI-202.
The transaction requires approval from Senti stockholders and satisfaction of other customary closing conditions. Definitive transaction documents will be filed with the SEC.
SENTI-202 carries meaningful clinical momentum — it holds FDA Regenerative Medicine Advanced Therapy designation and generated durable MRD-negative responses in a Phase I trial — but advancing it through late-stage development and potential commercialization demands capital and operational focus that a single company pursuing two distinct technology platforms would struggle to sustain simultaneously.
The company also said it has identified a donor characteristic—referred to as "Donor X"—that was associated with higher response rates in the Phase I study and plans to incorporate this donor selection strategy into future SENTI-202 manufacturing and clinical development.
By separating the Gene-Circuit-enabled pipeline into a privately held company, SNTI allows each organization to pursue distinct development strategies while giving existing stockholders continued economic exposure to SENTI-202 through the contingent value right.
Senti has indicated it will seek additional financing following close to fund its retained programs — suggesting the current balance sheet is insufficient to support both platforms independently.
The divestiture removes SENTI-202 and the broader Gene-Circuit franchise from Senti's consolidated pipeline. NewCo will also advance other Logic Gate-enabled programs for solid tumors and in vivo CAR approaches.